Introduction. Chronic pyelonephritis is the most common kidney disease. In accordance with the chronic nature of the infection, an important aspect of the treatment of recurrent uncomplicated urinary tract infections is antibiotic resistance. The aim of this work is to evaluate dynamics of the number of relapses and severity of symptoms of chronic pyelonephritis against the background of the complex drug «Nephrobac»®. Materials and methods. The study included 60 patients aged 24 to 56 years with complaints of pain in the lumbar area, fever, and dysuria. Based on the examination, the patients were diagnosed with chronic pyelonephritis. The patients were randomized into two groups: the first group received only antibacterial therapy, the second group received antibacterial therapy in combination with the biologically active complex «Nephrobac»® 1 capsule 2 times a day for 1 month. Patients of both groups were observed for 6 months from the start of therapy. Results. Fewer cases of leukocyturia were observed in the group receiving the antibiotic in combination with «Nephrobac»®, 45% and 75% after 3 and 6 months, respectively. In addition, in the same group, there were significantly fewer patients with bacteriuria after 3 visits in the main group compared with the control group receiving antibiotic therapy. There were no relapses registered 6 months after the start of the study in the group receiving combination therapy, including «Nephrobac»®, there were three patients with 1 relapse each in the control group. Conclusions. «Nephrobac»® can be recommended as a part of the complex therapy of chronic pyelonephritis, which has an anti-relapse and anti-inflammatory effect, enhancing antibiotics.
Introduction. Benign prostatic hyperplasia (BPH) is one of the most common diseases of the genitourinary system in men. Severe symptoms of lower urinary tract dysfunction (LUTS), which develop with BPH, worsen the quality of life. Prophylactic examinations, dynamic monitoring and necessary treatment: conservative (nonpharmacological and pharmacological treatment) or surgical treatment are necessary to control the course of the disease. Bioregulatory peptides can be used for early control of LUTS. The aim of the work was to assess the efficacy of early diagnosis and adherence to drug prophylaxis of BPH development and progression using different methods including bioregulatory peptides. Materials and methods. Data of the clinical examination and periodic medical examinations of 1675 men who were enrolled in the program «Complex of measures to increase the efficiency of early diagnostics of BPH and increase adherence to medical prophylaxis of BPH development and progression» were analyzed. After full clinical examination, depending on indications, patients were recommended surgical or conservative treatment – non-medication (behavioral) or medication (α1-adrenoblockers + muscarinic receptor antagonists, 5α-reductase inhibitors or Vitaprost preparations). The patients were observed for 4 years. Efficacy and safety of the use of bioregulatory peptides (Vitaprost®) in patients with BPH and LUTS were compared with the results of treatment in patients who chose behavioral therapy (active observation). Results. Behavioral therapy was used in 221 patients with mild to moderate symptoms, 312 patients were prescribed Vitaprost® Forte and Vitaprost® tablets. Active observation was more often chosen by patients of the youngest group (40-44 years). During Vitaprost® application there were improved IPSS questionnaire indexes, maximal urination rate increased, residual urine volume and prostate volume decreased. Worsening and increase of severity of complaints, according to IPSS questionnaire, decrease of maximum urinary flow rate and increase of residual urine volume and prostate volume were registered in actively observed group of patients. Conclusions. Timely initiation of therapy with Vitaprost® Forte and Vitaprost® tablets in patients with BPH has a favorable efficacy and safety profile. Further analysis of the data received as a result of the regional program is supposed to be carried out to evaluate its results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.